Experimental drug lepodisiran cuts heart disease risk factor by 94%
Lepodisiran, an experimental drug by Eli Lilly, reduces the risk of genetic heart disease by 94%. The drug significantly decreases Lp(a) levels, a genetically inherited risk for heart attacks and strokes, potentially offering a new treatment option for millions with high Lp(a) globally.
Lepodisiran, an experimental drug by Eli Lilly, reduces the risk of genetic heart disease by 94%. The drug significantly decreases Lp(a) levels, a genetically inherited risk for heart attacks and strokes, potentially offering a new treatment option for millions with high Lp(a) globally.
